Fulfilling the Promise of Personalized Medicine Through Next-Generation Sequencing

Published by	Decision Resources, Inc.
Published	November, 2008	Product code	77629
Content info	26 Pages
Price	US $ 2250 PDF by E-mail (Global License)

Introduction
Related Reports

Fulfilling the Promise of Personalized Medicine Through Next-Generation Sequencing published by Decision Resources, Inc. in November, 2008. This report consists of 26 Pages and the price starts from US $ 2250.

Introduction

Abstract

Introduction

The pharmaceutical industry has long criticized the slow uptake of new medicines in the United Kingdom. Beginning January 1, 2009, the U.K. government plans to implement measures to accelerate and widen access to innovative drugs. However, the pharmaceutical industry will be expected to adapt to a more fl exible pricing environment. In this report, we analyze the potential impact of the changes unveiled in November 2008.

Get the Answers You Need to Shape Your Strategy

The United Kingdom is one of the most accessible of all European pharmaceutical markets in terms of product registration, price setting, and reimbursement. How do U.K. prices compare with prices in other major markets? What are the procedures for price setting in the United Kingdom? How do manufacturers secure reimbursement for their products?
The U.K. government uses a more limited range of cost controls than most of its European neighbors.
How has the government used price cuts and freezes to curb spending? What measures have been implemented to stimulate the use of generics? How are prescribing budgets and audits used to modify physicians' prescribing behavior?
The National Institute for Health and Clinical Excellence (NICE) has become a very powerful infl uence on medical practice in England and Wales. How has the institute' s activity evolved over the years? How does the pharmaceutical industry view NICE? What measures have some companies adopted to overcome NICE' s rejection of their drugs? What changes has the government proposed to minimize any negative impact on access to medicines from NICE' s activity?
The government' s recently unveiled reform program includes some very welcome developments for the pharmaceutical industry. What measures are designed to accelerate the uptake of innovative therapies? What changes are expected to improve the reimbursement prospects of end-of-life treatments? What is the government doing to widen access to therapies not endorsed by NICE?
In return for these concessions, how will the government require greater pricing fl exibility from the pharmaceutical industry?

Scope

Organization and funding of the U.K. healthcare system: history of the National Health Service (NHS); healthcare spending in the United Kingdom; funding of the NHS; role of private healthcare in the United Kingdom; recent organizational changes to the NHS.
Pharmaceutical prices: comparison of prices in the United Kingdom and other major markets; pricing of branded prescription drugs based on new active substances, branded prescription drugs based on established active substances, and generic drugs; pricing in the hospital sector.
Cost-containment measures: price cuts and freezes; reimbursement restrictions; prescribing budgets and audits; local formularies; use of generics; parallel imports; patient copayments.
Health technology assessment: creation of the National Institute for Health and Clinical Excellence (NICE); industry criticisms; government response to parliamentary review of NICE; focus on oncology; risk-sharing and cost-sharing agreements.
Outlook for the U.K. pharmaceutical market: key trends; growing industry disillusionment with the U.K. market; promise of reform in draft NHS constitution; improving patient access to innovative medicines; implications for the pharmaceutical industry.

Mentioned in This Spectrum Report

Organizations

Advisory Committee on NHS Drugs (ACD)
American Pharmaceutical Group
Association of British Neurologists
Association of the British Pharmaceutical Industry
Bioindustry Association
Confederation of British Industry (CBI)
Department of Health
House of Commons Health Committee
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
Organization for Economic Cooperation and Development (OECD)
Prescription Pricing Authority (PPA)
World Health Organization (WHO)

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Overview
Challenging Times for the Drug Industry
How Industry Can Meet the Challenge
- Blockbuster Model Versus Personalized Medicine Model
- Back to the Basics: Genes
Mining the Genome for Pharmacogenomic Information
- The Human Genome Project.
- The HapMap Project
Key Commercial Activity in Haplotype Testing
- Affymetrix
- Illumina
- Applied Biosystems
- Perlegen
- Clinical Data
- Celera Genomics
Commercial Next-Generation Sequencing Systems
- Roche (454 Life Sciences)' s Platform
- Illumina (Solexa)' s Genome Analyzer
- Applied Biosystems' SOLiD Sequencer
- Helicos' s Helioscope
Next-Next-Generation Sequencing Systems - the Future?
NGS-Enabled Innovative Collaborations
- X Prize Foundation
- The 1000 Genomes Project
- The International Cancer Genome Organization
- The National Human Genome Research Institute
Outlook
- Gaining Improvements in Sequencing Methodology
- Enhancing Drug Discovery Applications
- Strengthening Biological Knowledge